The Effect of Glyburide on β-Cell Sensitivity to Glucose-Dependent Insulinotropic Polypeptide
The DOI matches its Crossref record.
Abstract
Objective— To assess whether treatment with glyburide alters β-cell sensitivity to GIP in NIDDM patients. Research Design and Methods— We studied 5 untreated NIDDM patients in a meal study (Ensure, 240 ml/M2) and a 2-h hyperglycemic glucose clamp study (glucose 5.4 mM above fasting). From 60 to 120 min of the clamp, GIP was infused in a primed continuous manner at a rate of 2 pmol·kg−1·min−1. Subjects then were treated with glyburide. After they had been on a stable dose of medication for 1 mo, the meal study and glucose clamp studies were repeated. Results— In response to treatment, a decrease in fasting glucose and an increase in weight was observed (12.8 ± 1.8 vs. 8.5 ± 0.8 mM and 74.3 ± 6.3 vs. 76.1 ± 6.3 kg, respectively, P < 0.05). In response to the meal study, the AUC for glucose was less, for insulin was increased, and for GIP was unchanged after treatment (16.9 ± 2.1 vs. 12.6 ± 6.9 mM, P <0.05; 161 ± 47 vs. 242 ± 60 pM, P < 0.05; and 199 ± 22 vs. 219 ± 18 pM, respectively). During the hyperglycemic clamp, steady-state glucose and 90- to 120-min GIP values were equivalent before and after treatment (18.0 ± 1.3 vs. 18.3 ± 1.3 mM and 302 ± 59 vs. 298 ± 37 pM, respectively). The 90b–120 min insulin responses to the hyperglycemic clamp were greater after therapy (123 ± 37 vs. 283 ± 80 pM, P < 0.05) reflecting increased β-cell responses to GIP. Conclusions— We conclude that glyburide enhances β-cell sensitivity to GIP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
“Previous studies have indicated that whereas GLP-1 is strongly insulinotropic in patients with Type II diabetes mellitus, the effect of GIP is much weaker or absent [5, 6]; although, in another study, GIP appeared to retain some activity [7].”
ResultGlucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors
Holst, J. J., & Deacon, C. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1705-7 · Cited by 288
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
GIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Metadata
- Authors
- Meneilly, G. S., Bryer-Ash, M., & Elahi, D.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1993-01-01
- Volume
- 16
- Issue
- 1
- Pages
- 110-114
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1992452630
- Cited by
- 40
- References
- 0
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Glyburide on β-Cell Sensitivity to Glucose-Dependent Insulinotropic Polypeptide. https://app.cochat.ai/papers/10.2337/diacare.16.1.110
- The paper
- Meneilly, G. S., Bryer-Ash, M., & Elahi, D. (1993). The Effect of Glyburide on β-Cell Sensitivity to Glucose-Dependent Insulinotropic Polypeptide. Diabetes Care. https://doi.org/10.2337/diacare.16.1.110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.